Abstract
Objective: The purpose of the current work was to comparatively assess 1470 nm diode laser enucleation of the prostate (DiLEP) and plasmakinetic resection of the prostate (PKRP) for treating benign prostatic hyperplasia (BPH).Patients and Methods: From January 2016 to March 2017, 157 individuals with bladder outflow obstruction caused by BPH were randomized to DiLEP and PKRP groups, for prospective analysis. Of these, 152 cases were evaluated before operation and at 3, 6, and 12 months postsurgery. Patient baseline properties, presurgery data, and postsurgical outcomes were comparatively assessed, as well as complications.Results: There were no significant preoperative differences between surgical groups. DiLEP-treated cases showed remarkable reduced operative time, postsurgical bladder irrigation time, catheterization duration, and hospital stay compared with the PKRP group (P < 0.001). Hemoglobin amount decrease was markedly less pronounced after DiLEP (P = 0.004). However, no patients needed blood transfusion in either group. The decrease in sodium level showed no marked differences between the DiLEP and PKRP groups (P = 0.380). In addition, complications were comparable and no significant differences in both groups. At 3, 6, and 12 months, International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and postvoid residual (PVR) were similar in both groups (P > 0.05).Conclusions: DiLEP and PKRP are similar in efficacy and safety for relieving obstruction and low urinary tract symptoms. Compared with PKRP, DiLEP has decreased risk of hemorrhage, operative time, bladder irrigation time, catheterization duration, and hospital stay. However, IPSS, QoL, Qmax, and PVR were similar for both procedures within 12 postoperative months.
Highlights
Benign prostatic hyperplasia (BPH) constitutes the major etiology of lower urinary tract symptoms (LUTS) in male individuals aged >50 years
The first laser enucleation of the prostate for BPH was described by Fraundorfer and Gilling in 1998.4 a variety of laser types, for example, holmium, thulium, potassium-titanyl-phosphate (KTP), and diode lasers, have been used for treating BPH.[5,6,7,8]
The current prospective, single-blinded RCT was conducted between January 2016 and March 2017 in our department; all cases with LUTS due to BPH with indication[11] for endosurgical treatment were invited to participate in this clinical study
Summary
Benign prostatic hyperplasia (BPH) constitutes the major etiology of lower urinary tract symptoms (LUTS) in male individuals aged >50 years. Transurethral resection of the prostate (TURP) represents the gold standard in the operative management of BPH, with demonstrated safety, efficacy, and durability.[1] important technologic advances in the last few decades have decreased surgeryrelated undesirable events, complications, including bleeding (0.3%), capsular perforation (0.1%), transfusion (2%), and transurethral resection syndrome (TURS; 0.8%), remain a great concern.[2] a novel minimally invasive technology has been proposed, with laser surgery considered the new standard.[3]. The first laser enucleation of the prostate for BPH was described by Fraundorfer and Gilling in 1998.4 a variety of laser types, for example, holmium, thulium, potassium-titanyl-phosphate (KTP), and diode lasers, have been used for treating BPH.[5,6,7,8] The first diode laser had approval from the U.S Food and Drug Administration (FDA) in
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
